HOME >> MEDICINE >> NEWS
Melanoma research receives a massive funding boost

NSW cancer researchers from the Sydney Melanoma Unit have received over $11 million to advance their world-leading research into the diagnosis and treatment of melanoma.

Australians have the highest rate of melanoma in the world, with incidence levels up to four times higher than the US and the UK, and up to ten times higher than most other countries.

Whilst it is the third most common cancer in Australia, it has proved to be one of the most difficult to manage. It most commonly affects those in the 30-45 year age group - people in the prime of their life- yet standard cancer treatments are often ineffective.

The Sydney Melanoma Unit is a group of cancer researchers and clinicians drawn from Westmead Millennium Institute, Newcastle Mater and Royal Prince Alfred Hospitals. It runs the largest melanoma treatment centre in the world, and with associated expertise in molecular diagnosis and treatment, provides our best hope for improving outcomes in people who develop, or are at risk of developing, melanoma.

This research group was recently recognised with a $3.75 million Program Grant from the Cancer Institute NSW. Today the Hon Tony Abbott, Commonwealth Minister for Health, announced that the Unit has also been awarded a prestigious National Health and Medical Research Council Program Grant, providing a further $7.8 million to support its vital research.

"Melanoma cells that have spread from their site of origin are notorious for being resistant to cancer treatment such as chemotherapy and radiotherapy" says Professor Richard Kefford, Chief Investigator of the successful Sydney Melanoma Unit NHMRC grant and researcher at Westmead Millennium Institute.

"These funds will allow us to progress our research into the molecular factors that determine an individual's risk of melanoma, so that we can identify the type of melanoma they have and how that disease will respond to treatments. We can then create more effective treatme
'"/>

Contact: Gayle McNaught
gayle_mcnaught@wmi.usyd.edu.au
61-298-459-009
Research Australia
6-Jul-2005


Page: 1 2

Related medicine news :

1. Summer update: Melanoma research progress suggests optimism for future cures
2. Melanoma vaccine strategy shows promise in laboratory experiments
3. Melanoma risk only partially associated vith exposure to UVB from sunlight
4. 1 of 2 pediatric kidney disease research centers in world established
5. Stanford researchers find culprit in aging muscles that heal poorly
6. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
7. Indiana University Imaging Center receives $6M grant for kidney research
8. Penn researchers discover novel pathway for increasing good cholesterol
9. New research discovers independent brain networks control human walking
10. Theory of facial aging gets a facelift from UT Southwestern researchers
11. Sports concussion research using fMRI provides insight for safe return-to-play decisions

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Melanoma research receives massive funding boost

(Date:4/23/2014)... "simple and accessible detection methods that can rapidly ... of a single cell inside that population has ... Chang Lu. , In the Royal Society of ... announced that he and his coworkers have developed ... of a protein ( Chem. Sci. , 2014, ...
(Date:4/23/2014)... are often displayed in the popular Swedish children,s ... of high-sugar foods. A new study from the ... in children,s TV programmes as well as the ... and weight status. , Steingerdur Olafsdottir,s doctoral thesis ... popular Swedish children,s TV show Bolibompa. Healthy foods ...
(Date:4/23/2014)... led by a researcher from the Cancer Science Institute ... Singapore has identified the cancer specific stem cell which ... of developing new drugs for the treatment of this ... group, led by Dr Chan Shing Leng, Research Assistant ... that a cancer-specific variant of a cell surface protein, ...
(Date:4/23/2014)... in the journal Oncotarget , explored tumour ... or their own DNA signatures within the same ... design effective, targeted treatment strategies. , Firstly they ... and either the KRAS or BRAF mutation. Secondly, ... EGFR gene mutation have that specific mutation present ...
(Date:4/23/2014)... Alzheimer,s disease has been a rapidly evolving pursuit ... latest crook in the research road, scientists have ... proteins associated with the disease. The report, which ... , could have important implications for developing novel ... colleagues explain that for years, research has suggested ...
Breaking Medicine News(10 mins):Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Cached News: